Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors
November 05, 2015 09:03 ET
|
Achillion Pharmaceuticals, Inc.
- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments – -...
Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference
November 02, 2015 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports Second Quarter and Six Month 2015 Financial Results
August 10, 2015 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2015. For the second...
$1.5 million gift to The Jackson Laboratory establishes Sims Family Fund for SMARD Research
August 05, 2015 16:08 ET
|
The Jackson Laboratory
BAR HARBOR, Maine, Aug. 5, 2015 (GLOBE NEWSWIRE) -- A $1.5 million gift to The Jackson Laboratory (JAX) from Mr. Grant Sims and Ms. Patricia (Patty) Sims of Houston, Texas, will fund research in a...
Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference
June 13, 2012 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
February 09, 2012 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
January 06, 2012 12:57 ET
|
Aegerion Pharmaceuticals, Inc.
Efficacy and Safety Profile Maintained
Company to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion...
Sandford D. Smith Appointed to Aegerion Pharmaceuticals' Board of Directors
December 20, 2011 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...